CytomX Therapeutics, Inc.
HealthcareNASDAQ:CTMX · NASDAQ Global Select
+$0.03 today
Vol 2.05M · Avg 6.88M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-17.5%
avg 1705.4%
ROIC
-20.5%
avg -22.7%
ROA
-11.5%
avg -16.6%
Analysis
ROA is currently the strongest return metric at -11.5% versus its period average of -16.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Sean A. McCarthy DPHIL | Chairman & Chief Executive Officer | $1.43M | — | 59 | $1.08M | 0.67% |
Christopher W. Ogden | SVP, CFO & Secretary | $871,334.00 | — | 42 | $296,948.00 | 0.18% |
Marcia Belvin | Senior Vice President & Chief Scientific Officer | $634,827.00 | — | 59 | $300,760.00 | 0.19% |
Lloyd A. Rowland Jr. | Senior Vice President, General Counsel, Chief Compliance Officer & Secretary | $608,718.00 | — | 69 | $1.08M | 0.67% |
Yu-Waye Chu | Senior VP & Chief Medical Officer | $496,938.00 | — | 58 | $189,446.00 | 0.12% |
Rachael Lester | Chief Business Officer & Senior Vice President | $241,519.00 | — | 48 | $50,000.00 | 0.03% |
Stephanie Robertson | Senior Vice President of Alliances & Program Leadership | — | — | — | — | — |
Danielle Olander-Moghadassian | Senior Vice President & Chief Human Resources Officer | — | — | — | — | — |
Dawn Benson | Senior Vice President of Quality & Product Manufacturing | — | — | — | — | — |
Leslie Robbins | Senior Vice President of Intellectual Property | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
9
$1.91M
Net Sentiment
$1.91M
Net selling
Most Active
McCarthy Sean A.
3 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 9 sells worth $1.91M over the last 12 months. That adds up to net selling of $1.91M. McCarthy Sean A. was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +141.6% | +8.4% (13yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +141.6% over three years. Forward estimates point to Revenue at +8.4% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Erasca, Inc.
NASDAQ:ERAS
$4.37B
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
$1.46B
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
$1.42B
MoonLake Immunotherapeutics
NASDAQ:MLTX
$1.38B
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
$1.19B
MeiraGTx Holdings plc
NASDAQ:MGTX
$888.13M
Replimune Group, Inc.
NASDAQ:REPL
$733.24M
Astria Therapeutics, Inc.
ATXS
$718.13M
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
$515.41M
Anavex Life Sciences Corp.
NASDAQ:AVXL
$231.68M
Who manages CTMX?
CytomX Therapeutics, Inc. (CTMX) lists 10 active executives. The top listed executive is Marcia Belvin, Senior Vice President & Chief Scientific Officer.
Are CTMX insiders buying or selling?
Recent insider activity shows net buying of $18.02M.
Explore More
Continue the stock analysis
Jump to another research area for this company.